Skip to main content

Advertisement

SpringerLink
Log in

Chemotherapy for metastatic gastric cancer in Japan

  • Review Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Until the 1990s, there were no chemotherapy regimens with old-generation anticancer agents showing a survival benefit over 5-fluorouracil (FU) alone, and standard chemotherapy for metastatic gastric cancer had not been established. In the late 1990s, several new active agents were developed and some phase III trials with these agents were conducted; the new agent S-1 showed noninferiority to 5-FU in these trials. S-1 plus cisplatin is the first doublet chemotherapy to have shown a survival benefit over monotherapy with S-1. It has been demonstrated that capecitabine and oxaliplatin (OHP) can replace 5-FU and cisplatin (CDDP), offering more convenient treatment options. Thus, combination chemotherapy with an oral fluoropyrimidine (S-1 or capecitabine) and platinum (CDDP or OHP) has been recognized as standard chemotherapy for metastatic gastric cancer all over the world. However, it can be said that none of these new combination chemotherapies have shown remarkable progress from 5-FU plus cisplatin regimens. It is expected that triplet chemotherapy with a taxane; the use of molecular targeting agents; and the establishment of treatment strategies including second line chemotherapy, will lead to remarkable progress in personalized medicine in the near future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, et al. (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108

    Article  PubMed  Google Scholar 

  2. Murad AM, Santiago FF, Petroianu A, et al. (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37–41

    Article  PubMed  CAS  Google Scholar 

  3. Glimelius B, Hoffmann K, Haglund U, et al. (1994) Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 5:189–190

    PubMed  CAS  Google Scholar 

  4. Pyrhonen S, Kuitumen T, Nyandoto P, et al. (1995) Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus best supportive care alone in patients with nonresectable gastric cancer. Br J Cancer 71:587–591

    PubMed  CAS  Google Scholar 

  5. Cullinan SA, Moertel CG, Fleming TR, et al. (1985) A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil versus fluorouracil and doxorubicin versus fluorouracil, doxorubicin, and mitomycin. JAMA 253:2061–2067

    Article  PubMed  CAS  Google Scholar 

  6. Wils JA, Klein HO, Wagener DJ, et al. (1991) Sequential high-dose methotrexate and fluorouracil, combined with doxorubicin: a step ahead in the treatment of gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 9:827–831

    PubMed  CAS  Google Scholar 

  7. Kelsen D, Atiq OT, Saltz L, et al. (1992) FAMTX versus etoposide, doxorubicin and cisplatin: a randomized trial in gastric cancer. J Clin Oncol 10:541–548

    PubMed  CAS  Google Scholar 

  8. Kim NK, Park YS, Heo DS, et al. (1993) A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71:3813–3918

    Article  PubMed  CAS  Google Scholar 

  9. Cullinan SA, Moertel CG, Wieand HS, et al. (1994) Controlled evaluation of three drug combination regimen versus fluorouracil alone in the therapy of advanced gastric cancer. J Clin Oncol 12:412–416

    PubMed  CAS  Google Scholar 

  10. Webb A, Cunningham D, Scarffe JH, et al. (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261–267

    PubMed  CAS  Google Scholar 

  11. Vanhoefer U, Rougier P, Wilke H, et al. (2000) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18:2648–2657

    PubMed  CAS  Google Scholar 

  12. Ohtsu A, Shimada Y, Shirao K, et al. (2003) Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21:54–59

    Article  PubMed  CAS  Google Scholar 

  13. Sakata Y, Ohtsu A, Horikoshi N, et al. (1998) Late phase II study of novel oral fluoropyrimidine aniticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715–1720

    Article  PubMed  CAS  Google Scholar 

  14. Koizumi W, Kurihara M, Nakano S, et al. (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 58:191–197

    Article  PubMed  CAS  Google Scholar 

  15. Boku N, Ohtsu A, Shimada Y, et al. (1999) A phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17:319–323

    PubMed  CAS  Google Scholar 

  16. Koizumi W, Tanabe S, Saigenji K, et al. (2003) Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 89:2207–2212

    Article  PubMed  CAS  Google Scholar 

  17. Takiuchi H, Narahara H, Tsujinaka T, et al.(2005) Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002). Jpn J Clin Oncol 35:520–525

    Article  PubMed  Google Scholar 

  18. Yoshida K, Hirabayashi N, Takiyama W, et al. (2004) Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. Anticancer Res 24:1843–1851

    PubMed  CAS  Google Scholar 

  19. Boku N, Yamamoto S, Shirao K, et al. (2007) Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). Annual meeting of ASCO, abstract #LBA4513T

  20. Koizumi W, Narahara H, Hara T, et al. (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215–221

    Article  PubMed  CAS  Google Scholar 

  21. Imamura H, IIishi H, Tsuburaya A, et al. (2008) Randomized phase III study of irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer (GC0301/TOP-002). ASCO Gastrointestinal Symposium, abstract #5

  22. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991–4997

    Article  PubMed  CAS  Google Scholar 

  23. Kang Y, Lee J, Min Y, et al. (2006) Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results. ASCO abstract# LBA4018

  24. Cunningham D, Starling N, Rao S, et al. (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36–46

    Article  PubMed  CAS  Google Scholar 

  25. Al-Batran SE, Hartmann JT, Probst S, et al. (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26:1435–1442

    Article  PubMed  CAS  Google Scholar 

  26. Shah MA, Ramanathan RK, Ilson DH, et al. (2006) Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24:5201–5206

    Article  PubMed  CAS  Google Scholar 

  27. Pinto C, Di Fabio F, Siena S, et al. (2007) Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 18:510–517

    Article  PubMed  CAS  Google Scholar 

  28. Muro K, Boku N, Yamada Y, et al. (2008) Multicenter phase II study of RAD001 for previously treated metastatic gastric cancer (MGC): preliminary results. Annual meeting of ASCO, abstract #4541

  29. Bang Y, Kang Y, Kang W, et al. (2007) Sunitinib as second-line treatment for advanced gastric cancer: preliminary results from a phase II study. Annual meeting of ASCO, abstract #4603

  30. Yano T, Doi T, Ohtsu A, et al. (2006) Comparison of HER2 gene amplification assessed by fluororescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 15:65–71

    PubMed  Google Scholar 

  31. Grothey A, Sargent D (2005) Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 23(36): 9441–9442

    Article  PubMed  Google Scholar 

  32. Hironaka S, Zenda S, Boku N, et al. (2006) Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 9:14–18

    Article  PubMed  CAS  Google Scholar 

  33. Ueda S, Hironaka S, Boku N, et al. (2006) Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer. Gastric Cancer 9:203–207

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Shizuoka, 411-8777, Japan

    Narikazu Boku

Authors
  1. Narikazu Boku
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Narikazu Boku.

About this article

Cite this article

Boku, N. Chemotherapy for metastatic gastric cancer in Japan. Int J Clin Oncol 13, 483–487 (2008). https://doi.org/10.1007/s10147-008-0847-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-008-0847-2

Key words

Search

Navigation